Treatment effect of capecitabine and docetaxel or docetaxel alone byoestrogen receptor status in patients with metastatic breast cancer: Results of an exploratory analysis

S. Glück, C. Russell, J. O'Shaughnessy, E. F. McKenna, S. Hu, D. Odom, J. L. Blum

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

We investigated treatment effects by oestrogen receptor (ER) status among women with metastatic breast cancer (MBC) receiving capecitabine (C) plus docetaxel (D) or D alone in a randomised phase III trial. Data were retrospectively analysed from patients whose disease had recurred following (neo)adjuvant anthracyclines. ER status was identified in 356/506 patients. In patients with ER-positive tumours, median overall survival from enrolment was 17.7 months with CD versus 12.5 months with D (hazard ratio [HR] 0.65, 95% confidence interval [CI]: 0.47-0.89; P=0.007) and median time to progression (TTP) was 6.8 and 5.4 months, respectively (HR 0.62, 95% CI: 0.46-0.84; P=0.002). For patients with ER-negative tumours, significantly longer TTP was seen with CD (5.2 versus 3.5 months; HR 0.73, 95% CI: 0.53-0.98; P=0.038). Whether there is an additional C to D treatment benefit in ER-positive versus ER-negative MBC requires further evaluation.

Original languageEnglish
Pages (from-to)1087-1093
Number of pages7
JournalBreast
Volume22
Issue number6
DOIs
StatePublished - Dec 1 2013
Externally publishedYes

Fingerprint

docetaxel
Breast Neoplasms
Confidence Intervals
Women's Rights
Anthracyclines
Therapeutics
Estrogen Receptors
Neoplasms
Survival
Capecitabine

Keywords

  • Capecitabine
  • Docetaxel
  • Exploratory analysis
  • Hormone receptor status
  • Metastatic breast cancer
  • Survival

ASJC Scopus subject areas

  • Surgery

Cite this

Treatment effect of capecitabine and docetaxel or docetaxel alone byoestrogen receptor status in patients with metastatic breast cancer : Results of an exploratory analysis. / Glück, S.; Russell, C.; O'Shaughnessy, J.; McKenna, E. F.; Hu, S.; Odom, D.; Blum, J. L.

In: Breast, Vol. 22, No. 6, 01.12.2013, p. 1087-1093.

Research output: Contribution to journalArticle

Glück, S. ; Russell, C. ; O'Shaughnessy, J. ; McKenna, E. F. ; Hu, S. ; Odom, D. ; Blum, J. L. / Treatment effect of capecitabine and docetaxel or docetaxel alone byoestrogen receptor status in patients with metastatic breast cancer : Results of an exploratory analysis. In: Breast. 2013 ; Vol. 22, No. 6. pp. 1087-1093.
@article{b1d092ffe5b641fe933a4e933c74b90b,
title = "Treatment effect of capecitabine and docetaxel or docetaxel alone byoestrogen receptor status in patients with metastatic breast cancer: Results of an exploratory analysis",
abstract = "We investigated treatment effects by oestrogen receptor (ER) status among women with metastatic breast cancer (MBC) receiving capecitabine (C) plus docetaxel (D) or D alone in a randomised phase III trial. Data were retrospectively analysed from patients whose disease had recurred following (neo)adjuvant anthracyclines. ER status was identified in 356/506 patients. In patients with ER-positive tumours, median overall survival from enrolment was 17.7 months with CD versus 12.5 months with D (hazard ratio [HR] 0.65, 95{\%} confidence interval [CI]: 0.47-0.89; P=0.007) and median time to progression (TTP) was 6.8 and 5.4 months, respectively (HR 0.62, 95{\%} CI: 0.46-0.84; P=0.002). For patients with ER-negative tumours, significantly longer TTP was seen with CD (5.2 versus 3.5 months; HR 0.73, 95{\%} CI: 0.53-0.98; P=0.038). Whether there is an additional C to D treatment benefit in ER-positive versus ER-negative MBC requires further evaluation.",
keywords = "Capecitabine, Docetaxel, Exploratory analysis, Hormone receptor status, Metastatic breast cancer, Survival",
author = "S. Gl{\"u}ck and C. Russell and J. O'Shaughnessy and McKenna, {E. F.} and S. Hu and D. Odom and Blum, {J. L.}",
year = "2013",
month = "12",
day = "1",
doi = "10.1016/j.breast.2013.08.016",
language = "English",
volume = "22",
pages = "1087--1093",
journal = "Breast",
issn = "0960-9776",
publisher = "Churchill Livingstone",
number = "6",

}

TY - JOUR

T1 - Treatment effect of capecitabine and docetaxel or docetaxel alone byoestrogen receptor status in patients with metastatic breast cancer

T2 - Results of an exploratory analysis

AU - Glück, S.

AU - Russell, C.

AU - O'Shaughnessy, J.

AU - McKenna, E. F.

AU - Hu, S.

AU - Odom, D.

AU - Blum, J. L.

PY - 2013/12/1

Y1 - 2013/12/1

N2 - We investigated treatment effects by oestrogen receptor (ER) status among women with metastatic breast cancer (MBC) receiving capecitabine (C) plus docetaxel (D) or D alone in a randomised phase III trial. Data were retrospectively analysed from patients whose disease had recurred following (neo)adjuvant anthracyclines. ER status was identified in 356/506 patients. In patients with ER-positive tumours, median overall survival from enrolment was 17.7 months with CD versus 12.5 months with D (hazard ratio [HR] 0.65, 95% confidence interval [CI]: 0.47-0.89; P=0.007) and median time to progression (TTP) was 6.8 and 5.4 months, respectively (HR 0.62, 95% CI: 0.46-0.84; P=0.002). For patients with ER-negative tumours, significantly longer TTP was seen with CD (5.2 versus 3.5 months; HR 0.73, 95% CI: 0.53-0.98; P=0.038). Whether there is an additional C to D treatment benefit in ER-positive versus ER-negative MBC requires further evaluation.

AB - We investigated treatment effects by oestrogen receptor (ER) status among women with metastatic breast cancer (MBC) receiving capecitabine (C) plus docetaxel (D) or D alone in a randomised phase III trial. Data were retrospectively analysed from patients whose disease had recurred following (neo)adjuvant anthracyclines. ER status was identified in 356/506 patients. In patients with ER-positive tumours, median overall survival from enrolment was 17.7 months with CD versus 12.5 months with D (hazard ratio [HR] 0.65, 95% confidence interval [CI]: 0.47-0.89; P=0.007) and median time to progression (TTP) was 6.8 and 5.4 months, respectively (HR 0.62, 95% CI: 0.46-0.84; P=0.002). For patients with ER-negative tumours, significantly longer TTP was seen with CD (5.2 versus 3.5 months; HR 0.73, 95% CI: 0.53-0.98; P=0.038). Whether there is an additional C to D treatment benefit in ER-positive versus ER-negative MBC requires further evaluation.

KW - Capecitabine

KW - Docetaxel

KW - Exploratory analysis

KW - Hormone receptor status

KW - Metastatic breast cancer

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84887135458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887135458&partnerID=8YFLogxK

U2 - 10.1016/j.breast.2013.08.016

DO - 10.1016/j.breast.2013.08.016

M3 - Article

C2 - 24095220

AN - SCOPUS:84887135458

VL - 22

SP - 1087

EP - 1093

JO - Breast

JF - Breast

SN - 0960-9776

IS - 6

ER -